Mean % change from baseline (95% confidence interval) | Pvalue* (300 mg vs. 100 mg) | ||
---|---|---|---|
Vandetanib 100 mg | Vandetanib 300 mg | ||
Primary variables | |||
iAUC60 | --3.4 (--13.6, 8.1) | --4.6 (--13.4, 5.0) | 0.429 (one-sided) |
Ktrans | --4.6 (--22.4, 17.4) | --2.7 (--18.4, 16.2) | 0.558 (one-sided) |
Exploratory variables | |||
T2* | --2.2 (--7.1, 2.9) | 7.3 (3.1, 11.7) | 0.006 (two-sided) |
LDDCE-MRI | 16.1 (9.7, 22.9) | 8.0 (2.9, 13.4) | 0.029 (one-sided) |